Abbvie Inc ABBV

$286.20 +2.66 (0.94%)

Valuation

Market cap
505,891,712,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
P/E (trailing)
22.10
P/E (forward)
20.27
Profit margin
6.91%
Debt to equity
-17.83

Trading

Volume
8,769,700
Avg volume
5,056,360
Day's range
$284.85 – $290.23
Shares out
1,767,616,000
Stochastic %K
30%
Beta
0.20
Analysts
Moderate Buy
Price target
$314.50

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

Princeb Nov 22, 4:28 AM
$MRK $ABBV $JNJ $PFE who wants this beauty $SLS
1 replies
55X_ROI_Q1_2026 Nov 22, 3:45 AM
$SLS $MRK has an Inside View of GPS Immunogenicity and Efficacy. GPS + Keytruda PH1/2 Published Trial Data - Solid Tumor, Platinum Resistant Ovarian Cancer MOS of 18.4 months is Better than SOC / 16.46 months Elahere $ABBV - paid $10B for Elahere $MRK has just been waiting for the P3 REGAL AML results in order to Pay Angies $40B Max Value. Again. Gps is worth at Least the $10B ABBV Paid for Elahere in PROC.
0 replies
10xorbust Nov 22, 12:57 AM
$SLS $JNJ $MRK $PFE $ABBV are all going to line up to buy $SLS. Open up that checkbook.
1 replies
55X_ROI_Q1_2026 Nov 21, 7:31 PM
$SLS Gps P3 Stat Sig MOS of 24 months will continue to lengthen with additional follow-up - as the long tail of 46 mostly Gps survivors continue to survive. Took 5.5 months for the 79th and 80th event. Bottom line, Gps Phase 3 MOS for CR2 ”and later” is longer than SOC / BAT for CR1. $BMY $RHHBY $ABBV who own Onureg and Venetoclax are already fighting over Gps. https://www.fiercepharma.com/pharma/inside-abbvies-10b-immunogen-buyout-and-bidding-war-it-won
0 replies
LilyR Nov 21, 6:30 PM
$SLS Bidding war , 4 Big Pharma Suitors 1️⃣ Merck ($MRK): Already ran clinical combos of GPS + Keytruda (showing strong survival data in ovarian cancer). With Keytruda’s 2028 patent cliff looming, an off-the-shelf vaccine is the ultimate combo shield. 2️⃣ Bristol Myers Squibb ($BMY): The undisputed king of hematology (Onureg, Reblozyl) + facing Opdivo’s patent cliff. GPS fits straight into BMY’s existing AML salesforce on Day 1 while boosting Opdivo in solid tumors. 3️⃣ AbbVie ($ABBV): Venclexta dominates frontline AML induction—GPS is the logical next step for post-remission maintenance, creating a complete end-to-end AML franchise (plus CDK9 inhibitor SLS009 as a bonus). 4️⃣ AstraZeneca ($AZN) / Roche: Both are aggressively expanding PD-L1s (Imfinzi / Tecentriq) into early-stage/adjuvant settings where GPS shines by clearing minimal residual disease. Off-the-shelf + Phase 3 validated + multi-tumor scalability = prime M&A tension.
4 replies
SellasGPS24BAT14 Nov 21, 5:45 PM
$SLS $JNJ $BMY $ABBV $PFE Entire November 2026 SELLAS Life Sciences Group Corporate Presentation posted on the website caters to Big Pharmaceutical Suitors. I expect a deal in coming days. ✌️🙏❤️‍🩹
0 replies
55X_ROI_Q1_2026 Nov 20, 8:03 PM
$SLS $3B Market Cap for a revolutionary WT1+ Cancer Vaccine that will Generate $10B a year just in the AML Remission Setting. • manipulation offering the Investment Opportunity of our Lifetimes. GPs + Keytruda $MRK Phase 2 MOS of 18.4 Months in Advanced Ovarian Cancer/ is better than Standard of Care Elahere 16.46 months. $ABBV bought $IMGN Elahere for $10.1B Get em while they'e cheap.
0 replies
55X_ROI_Q1_2026 Nov 20, 7:49 PM
$SLS $MRK $ABBV Ceo transcript estimating Cr2 market Scope. Revenue could top $10B Per YEAR --- Just for AML Remission Maintenance Will set record patient uptake rates - 75% is current standard w new drugs - 2x 3x OS Advantage / Pristine Safety 100% QoL /in home Sub Q • 12,500 CR2/3 Patients • $500K Per Patient • $6.25B TAM Just for the Initial P3 Setting 75% uptake -- $4.7B in Actual Revenue Just from the Cr2/3 setting that $4B alone is worth 6x -8x multiple •• $24B - $28B 215M shares Float / $24B $111 Per SLS SHARE * - includes Latest Offering - again just Cr2/3 - which is inaccurate, as GPS P3 MOS for Cr2/ and LATER - is as good as Standard of Care / Onureg in CR1 GPS will Also be Valued for this Much Larger Indication 50,000 AML CR1 Patients Each YEAR --- the math is boggling. the current discounted share price is an aberration. $MRNA $XBI
0 replies